ClientEarth call for action on unreasonable delays and lack of transparency in the adoption of authorisations and restrictions under REACH

The Commission is in charge of adopting the final decision on whether to authorise the use of substances of very high concern, or whether to restrict the use of substances with unacceptable risks. It has to do so on the basis of the scientific opinions provided by the European Chemical Agency’s committees, and with the support of experts from the Member States.

In June 2018, ClientEarth did a systematic review of the time it has taken the Commission to adopt this decisions since the beginning of REACH. It uncovered that the decisions have suffered from unreasonable delays, which resulted in the continued use of some substances known to be harmful.

Since then, ClientEarth has met with the Commission and received a reply to its letter in July 2018. In this letter sent on December 11th, ClientEarth takes stock of the progresses accomplished so far, calls for further actions and answers in detail the letter from the Commission.

See the original letter here

Size 301 KB
Published December 11, 2018
Found in ChemicalsHealthREACH